Plain-English translation of NCT05500469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Glaucoma is an eye disease that damages the optic nerve and causes vision loss. This trial is testing the Paul glaucoma drainage device—a small implant that helps lower pressure inside the eye—by comparing two different ways to position its tube during surgery. One approach places the tube in front of the iris (the colored part of your eye), while the other places it behind the iris.
When the drainage tube is placed in front of the iris, it can damage the clear cells that cover the cornea (the front of your eye), potentially leading to corneal clouding over time. This trial wants to see if placing the tube behind the iris instead reduces this damage while still controlling glaucoma effectively.
You likely qualify if…
You likely don't qualify if…
You will receive the Paul glaucoma drainage device implant surgery, with your surgical team randomly assigning you to have the tube placed either in front of or behind your iris. After surgery, you'll attend follow-up visits where doctors will examine your eye and take special photographs to count the cells on your cornea, measuring how well each placement protects your eye. The study visits will take approximately 2 hours total across multiple appointments over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Netherlands